NASDAQ:EOLS Evolus - EOLS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.46 +0.11 (+1.32%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.27▼$8.5650-Day Range$8.07▼$11.0452-Week Range$6.51▼$14.34Volume328,024 shsAverage Volume528,039 shsMarket Capitalization$477.23 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Evolus MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside89.1% Upside$16.00 Price TargetShort InterestBearish5.21% of Float Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.07Based on 2 Articles This WeekInsider TradingSelling Shares$34.73 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.50) to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector578th out of 1,004 stocksPharmaceutical Preparations Industry278th out of 489 stocks 3.4 Analyst's Opinion Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Evolus has a forecasted upside of 89.1% from its current price of $8.46.Amount of Analyst CoverageEvolus has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.21% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Evolus has recently decreased by 0.90%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEvolus has received a 40.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private dermatologist's appointments", "Private internist's appointments", and "Botulinum toxin" products. See details.Environmental SustainabilityThe Environmental Impact score for Evolus is -1.27. Previous Next 1.2 News and Social Media Coverage News SentimentEvolus has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Evolus this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,729,462.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Evolus is held by insiders.Percentage Held by Institutions45.41% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.50) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -6.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -6.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvolus has a P/B Ratio of 25.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Evolus (NASDAQ:EOLS) StockEvolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.Read More Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address EOLS Stock News HeadlinesMarch 30, 2023 | americanbankingnews.comEvolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 6,110 SharesMarch 11, 2023 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call TranscriptApril 1, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.March 8, 2023 | finance.yahoo.comEvolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue EstimatesJanuary 30, 2023 | finance.yahoo.comInstitutional investors own a significant stake of 39% in Evolus, Inc. (NASDAQ:EOLS)January 30, 2023 | finance.yahoo.comEvolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown LinesJanuary 20, 2023 | finance.yahoo.comWhy Evolus Shares Jumped This WeekJanuary 19, 2023 | finance.yahoo.comHere's Why This Analyst Seems Highly Convinced With Evolus' OutlookApril 1, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.January 13, 2023 | ca.finance.yahoo.comEvolus, Inc. (EOLS) Stock Historical Prices & Data - Yahoo FinanceJanuary 3, 2023 | finance.yahoo.comEvolus, Inc.'s (NASDAQ:EOLS) Shift From Loss To ProfitNovember 10, 2022 | finance.yahoo.comEvolus Third Quarter 2022 Earnings: Revenues DisappointNovember 9, 2022 | finance.yahoo.comEvolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue EstimatesOctober 26, 2022 | nz.finance.yahoo.comEvolus to Report Third Quarter 2022 Results and Provide Business UpdateOctober 13, 2022 | nasdaq.comWith 42% ownership, Evolus, Inc. (NASDAQ:EOLS) has piqued the interest of institutional investorsOctober 8, 2022 | reuters.comEOLS.O - Evolus Inc | Stock Price & Latest News | ReutersOctober 4, 2022 | businesswire.comEvolus Broadens Its International Presence with Nuceiva® Launch in Great Britain - Business WireSeptember 20, 2022 | finance.yahoo.comHarpoon Therapeutics Appoints Lauren Silvernail to Board of Directors - Yahoo FinanceSeptember 19, 2022 | streetinsider.comHarpoon Therapeutics (HARP) Appoints Lauren Silvernail to Board of Directors - StreetInsider.comSeptember 18, 2022 | realmoney.thestreet.comThis Options Play Could Turn That Frown Upside Down - RealMoneySeptember 11, 2022 | seekingalpha.comEvolus Stock: Turning That Frown Upside Down (NASDAQ:EOLS) - Seeking AlphaSeptember 9, 2022 | barrons.comU.K. Saw Enormous Growth Under Queen Elizabeth II. Global Markets Could Use Her Stability. - Barron'sSeptember 9, 2022 | uk.investing.comEvolus Director Trades $184K In Company Stock By Benzinga - Investing.com UKSeptember 8, 2022 | barrons.comBiden, First Lady's Thoughts 'Solidly And Squarely' With Queen: W.House - Barron'sSeptember 8, 2022 | benzinga.comEvolus (NASDAQ:EOLS) – Evolus Director Trades $184K In Company Stock - BenzingaSeptember 7, 2022 | nasdaq.comThe Last 12 Months Of Insider Transactions At EvolusSeptember 7, 2022 | ca.finance.yahoo.comPublic Advisory - Counterfeit Nuceiva injectable drug seized from New You Spa in Vaughan, Ontario - Yahoo Canada FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address EOLS Company Calendar Last Earnings3/08/2023Today3/31/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EOLS CUSIPN/A CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees167Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+89.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,410,000.00 Net Margins-50.07% Pretax Margin-50.01% Return on Equity-178.39% Return on Assets-35.98% Debt Debt-to-Equity Ratio3.89 Current Ratio2.17 Quick Ratio1.76 Sales & Book Value Annual Sales$148.62 million Price / Sales3.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book25.64Miscellaneous Outstanding Shares56,410,000Free Float52,294,000Market Cap$477.23 million OptionableOptionable Beta1.93 Key ExecutivesDavid MoatazediPresident, Chief Executive Officer & DirectorSandra BeaverChief Financial OfficerRui AvelarChief Medical Officer, Head-Research & DevelopmentDan StewartVice President & General ManagerChristos MonovoukasSenior Vice President-Corporate DevelopmentKey CompetitorsAerovate TherapeuticsNASDAQ:AVTEEmergent BioSolutionsNYSE:EBSMersana TherapeuticsNASDAQ:MRSNEntrada TherapeuticsNASDAQ:TRDATerns PharmaceuticalsNASDAQ:TERNView All CompetitorsInsiders & InstitutionsDavid MoatazediSold 6,110 sharesTotal: $51,751.70 ($8.47/share)David MoatazediSold 64,211 sharesTotal: $543,867.17 ($8.47/share)Alphaeon 1 LlcSold 1,850,000 sharesTotal: $15.54 M ($8.40/share)Caligan Partners LPBought 1,740,700 shares on 2/16/2023Ownership: 3.095%AIGH Capital Management LLCBought 728,528 shares on 2/16/2023Ownership: 1.651%View All Insider TransactionsView All Institutional Transactions EOLS Stock - Frequently Asked Questions Should I buy or sell Evolus stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EOLS shares. View EOLS analyst ratings or view top-rated stocks. What is Evolus' stock price forecast for 2023? 5 brokerages have issued 1 year price objectives for Evolus' stock. Their EOLS share price forecasts range from $10.00 to $20.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 89.1% from the stock's current price. View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts. How have EOLS shares performed in 2023? Evolus' stock was trading at $7.51 on January 1st, 2023. Since then, EOLS stock has increased by 12.6% and is now trading at $8.46. View the best growth stocks for 2023 here. When is Evolus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our EOLS earnings forecast. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) released its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. The firm had revenue of $43.65 million for the quarter, compared to analysts' expectations of $43.48 million. Evolus had a negative trailing twelve-month return on equity of 178.39% and a negative net margin of 50.07%. What ETFs hold Evolus' stock? ETFs with the largest weight of Evolus (NASDAQ:EOLS) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB) and What guidance has Evolus issued on next quarter's earnings? Evolus issued an update on its FY 2023 earnings guidance on Thursday, March, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.00 million-$190.00 million, compared to the consensus revenue estimate of $186.62 million. What is David Moatazedi's approval rating as Evolus' CEO? 1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Organigram (OGI) and Bionano Genomics (BNGO). When did Evolus IPO? (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. What is Evolus' stock symbol? Evolus trades on the NASDAQ under the ticker symbol "EOLS." Who are Evolus' major shareholders? Evolus' stock is owned by a number of institutional and retail investors. Top institutional investors include First Manhattan Co. (7.14%), Caligan Partners LP (3.09%), Millennium Management LLC (2.59%), Boothbay Fund Management LLC (1.92%), AIGH Capital Management LLC (1.65%) and Stonepine Capital Management LLC (1.48%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar and Vikram Malik. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Evolus' stock price today? One share of EOLS stock can currently be purchased for approximately $8.46. How much money does Evolus make? Evolus (NASDAQ:EOLS) has a market capitalization of $477.23 million and generates $148.62 million in revenue each year. The company earns $-74,410,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. How many employees does Evolus have? The company employs 167 workers across the globe. How can I contact Evolus? Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com. This page (NASDAQ:EOLS) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.